I
I. E. M. Den Uijl
Researcher at Oklahoma State University Center for Health Sciences
Publications - 7
Citations - 584
I. E. M. Den Uijl is an academic researcher from Oklahoma State University Center for Health Sciences. The author has contributed to research in topics: Haemophilia & Haemophilia A. The author has an hindex of 7, co-authored 7 publications receiving 472 citations. Previous affiliations of I. E. M. Den Uijl include Utrecht University & University of Michigan.
Papers
More filters
Journal ArticleDOI
Clinical severity of haemophilia A: does the classification of the 1950s still stand?
I. E. M. Den Uijl,E. P. Mauser Bunschoten,G. Roosendaal,Roger E. G. Schutgens,Douwe H. Biesma,Diederick E. Grobbee,Krista Fischer +6 more
TL;DR: This study confirms the clinical distinction between severe and non‐severe haemophilia A, however, the group of moderate haenophilia patients showed a wide variability, warranting close follow‐up and individualized treatment.
Journal ArticleDOI
Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels
I. E. M. Den Uijl,Krista Fischer,J. G. van der Bom,Diederick E. Grobbee,F. R. Rosendaal,I. Plug +5 more
TL;DR: This study investigated the optimal analysing strategy for bleeding data by using the association of residual clotting factor level and number of joint bleeds in moderate and mild patients treated on demand as example, and found Multivariate regression analysis using negative binomial distribution provided the optimum data analytical strategy.
Journal ArticleDOI
Clinical outcome of moderate haemophilia compared with severe and mild haemophilia
I. E. M. Den Uijl,Krista Fischer,J. G. van der Bom,Diederick E. Grobbee,F. R. Rosendaal,I. Plug +5 more
TL;DR: Although outcome in moderate haemophilia is generally in between severe and mild haenophilia, moderate ha Hemophilia patients reported a substantial burden of disease, and for more than 25% of patients with moderate haEMophilia long term prophylaxis was implemented because of frequent bleeds.
Journal ArticleDOI
Risk of inhibitor development in mild haemophilia A increases with age.
Evelien P. Mauser-Bunschoten,I. E. M. Den Uijl,Roger E. G. Schutgens,Goris Roosendaal,Krista Fischer +4 more
TL;DR: Although the incidence of inhibitors in mild haemophilia is low, it increases with age and peak treatments, and especially patients with a change of arginine in cysteine at 593 are at risk for inhibitor development.
Journal ArticleDOI
Magnetic resonance imaging in teenagers and young adults with limited haemophilic arthropathy: baseline results from a prospective study.
TL;DR: Haemosiderin seemed associated with the time between assessment and last bleed; joints that had suffered a bleed long before MRI had hardly haemOSiderin, while those with a recent bleed showed haemosIDERin, suggesting joint damage may be reversible.